Cell Death & Disease:caveolin-1在前列腺癌进展过程中对旁分泌诱导的研究

2019-11-20 AlexYang MedSci原创

一类癌症干细胞(CSCs)亚群在癌症进展、复发和治疗抗性中具有重要的作用。许多研究表明了去势抵抗性前列腺啊(CRPC)与干细胞的表型相关,这些干细胞能够进一步促进神经内分泌转分化。尽管在每种器官中只有一小部分基因预编程细胞具有干细胞能力,CSCs在遗传异质性癌症细胞群体中可能是能够诱导的。然而,导致这些CSCs出现的诱导机制在CRPC中仍旧没有完全清楚。肿瘤细胞能够产生、释放和使用外泌体来促进癌症

一类癌症干细胞(CSCs)亚群在癌症进展、复发和治疗抗性中具有重要的作用。许多研究表明了去势抵抗性前列腺啊(CRPC)与干细胞的表型相关,这些干细胞能够进一步促进神经内分泌转分化。尽管在每种器官中只有一小部分基因预编程细胞具有干细胞能力,CSCs在遗传异质性癌症细胞群体中可能是能够诱导的。然而,导致这些CSCs出现的诱导机制在CRPC中仍旧没有完全清楚。肿瘤细胞能够产生、释放和使用外泌体来促进癌症发展、转移、癌症免疫浸润和化疗抗性;肿瘤来源的外泌体(TDE)和其携带的"货物"对前列腺癌(PCa)发展的影响仍旧不清楚。

最近,有研究人员阐释了TDE中的Cav-1在通过NFκB信号通路正在进行神经内分泌分化的PCa中能够驱使诱导CSC表型和上皮-间质转化。更多的是,mCRPC来源的外泌体中的Cav-1能够诱导受体细胞放疗和化疗抗性。最后,研究人员指出,他们的数据表明了Cav-1是mCRPC发展的关键驱使因子。

原始出处:

Chun-Jung Lin, Eun-Jin Yun, U-Ging Lo et al. The paracrine induction of prostate cancer progression by caveolin-1. Cell Death & Disease. 04 Nov 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1682579, encodeId=1bb916825e963, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Wed Oct 07 14:46:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013100, encodeId=60cf20131001a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 17 18:46:00 CST 2020, time=2020-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871487, encodeId=35a018e14876e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Oct 23 11:46:00 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752373, encodeId=48ba1e523737d, content=<a href='/topic/show?id=82744169af' target=_blank style='color:#2F92EE;'>#caveolin-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4169, encryptionId=82744169af, topicName=caveolin-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7aa036514870, createdName=karmond, createdTime=Mon Jul 27 23:46:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961776, encodeId=05ec1961e76b5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Oct 30 20:46:00 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531485, encodeId=0d961531485da, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri Nov 22 04:46:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629921, encodeId=02c6162992107, content=<a href='/topic/show?id=cb9c5881310' target=_blank style='color:#2F92EE;'>#旁分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58813, encryptionId=cb9c5881310, topicName=旁分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=422221388033, createdName=lfcmxl, createdTime=Fri Nov 22 04:46:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040595, encodeId=5555104059502, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Nov 20 16:46:00 CST 2019, time=2019-11-20, status=1, ipAttribution=)]
    2020-10-07 gwc392
  2. [GetPortalCommentsPageByObjectIdResponse(id=1682579, encodeId=1bb916825e963, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Wed Oct 07 14:46:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013100, encodeId=60cf20131001a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 17 18:46:00 CST 2020, time=2020-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871487, encodeId=35a018e14876e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Oct 23 11:46:00 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752373, encodeId=48ba1e523737d, content=<a href='/topic/show?id=82744169af' target=_blank style='color:#2F92EE;'>#caveolin-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4169, encryptionId=82744169af, topicName=caveolin-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7aa036514870, createdName=karmond, createdTime=Mon Jul 27 23:46:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961776, encodeId=05ec1961e76b5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Oct 30 20:46:00 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531485, encodeId=0d961531485da, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri Nov 22 04:46:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629921, encodeId=02c6162992107, content=<a href='/topic/show?id=cb9c5881310' target=_blank style='color:#2F92EE;'>#旁分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58813, encryptionId=cb9c5881310, topicName=旁分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=422221388033, createdName=lfcmxl, createdTime=Fri Nov 22 04:46:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040595, encodeId=5555104059502, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Nov 20 16:46:00 CST 2019, time=2019-11-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1682579, encodeId=1bb916825e963, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Wed Oct 07 14:46:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013100, encodeId=60cf20131001a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 17 18:46:00 CST 2020, time=2020-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871487, encodeId=35a018e14876e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Oct 23 11:46:00 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752373, encodeId=48ba1e523737d, content=<a href='/topic/show?id=82744169af' target=_blank style='color:#2F92EE;'>#caveolin-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4169, encryptionId=82744169af, topicName=caveolin-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7aa036514870, createdName=karmond, createdTime=Mon Jul 27 23:46:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961776, encodeId=05ec1961e76b5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Oct 30 20:46:00 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531485, encodeId=0d961531485da, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri Nov 22 04:46:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629921, encodeId=02c6162992107, content=<a href='/topic/show?id=cb9c5881310' target=_blank style='color:#2F92EE;'>#旁分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58813, encryptionId=cb9c5881310, topicName=旁分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=422221388033, createdName=lfcmxl, createdTime=Fri Nov 22 04:46:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040595, encodeId=5555104059502, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Nov 20 16:46:00 CST 2019, time=2019-11-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1682579, encodeId=1bb916825e963, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Wed Oct 07 14:46:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013100, encodeId=60cf20131001a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 17 18:46:00 CST 2020, time=2020-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871487, encodeId=35a018e14876e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Oct 23 11:46:00 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752373, encodeId=48ba1e523737d, content=<a href='/topic/show?id=82744169af' target=_blank style='color:#2F92EE;'>#caveolin-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4169, encryptionId=82744169af, topicName=caveolin-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7aa036514870, createdName=karmond, createdTime=Mon Jul 27 23:46:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961776, encodeId=05ec1961e76b5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Oct 30 20:46:00 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531485, encodeId=0d961531485da, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri Nov 22 04:46:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629921, encodeId=02c6162992107, content=<a href='/topic/show?id=cb9c5881310' target=_blank style='color:#2F92EE;'>#旁分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58813, encryptionId=cb9c5881310, topicName=旁分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=422221388033, createdName=lfcmxl, createdTime=Fri Nov 22 04:46:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040595, encodeId=5555104059502, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Nov 20 16:46:00 CST 2019, time=2019-11-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1682579, encodeId=1bb916825e963, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Wed Oct 07 14:46:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013100, encodeId=60cf20131001a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 17 18:46:00 CST 2020, time=2020-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871487, encodeId=35a018e14876e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Oct 23 11:46:00 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752373, encodeId=48ba1e523737d, content=<a href='/topic/show?id=82744169af' target=_blank style='color:#2F92EE;'>#caveolin-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4169, encryptionId=82744169af, topicName=caveolin-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7aa036514870, createdName=karmond, createdTime=Mon Jul 27 23:46:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961776, encodeId=05ec1961e76b5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Oct 30 20:46:00 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531485, encodeId=0d961531485da, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri Nov 22 04:46:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629921, encodeId=02c6162992107, content=<a href='/topic/show?id=cb9c5881310' target=_blank style='color:#2F92EE;'>#旁分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58813, encryptionId=cb9c5881310, topicName=旁分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=422221388033, createdName=lfcmxl, createdTime=Fri Nov 22 04:46:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040595, encodeId=5555104059502, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Nov 20 16:46:00 CST 2019, time=2019-11-20, status=1, ipAttribution=)]
    2020-10-30 维他命
  6. [GetPortalCommentsPageByObjectIdResponse(id=1682579, encodeId=1bb916825e963, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Wed Oct 07 14:46:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013100, encodeId=60cf20131001a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 17 18:46:00 CST 2020, time=2020-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871487, encodeId=35a018e14876e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Oct 23 11:46:00 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752373, encodeId=48ba1e523737d, content=<a href='/topic/show?id=82744169af' target=_blank style='color:#2F92EE;'>#caveolin-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4169, encryptionId=82744169af, topicName=caveolin-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7aa036514870, createdName=karmond, createdTime=Mon Jul 27 23:46:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961776, encodeId=05ec1961e76b5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Oct 30 20:46:00 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531485, encodeId=0d961531485da, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri Nov 22 04:46:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629921, encodeId=02c6162992107, content=<a href='/topic/show?id=cb9c5881310' target=_blank style='color:#2F92EE;'>#旁分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58813, encryptionId=cb9c5881310, topicName=旁分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=422221388033, createdName=lfcmxl, createdTime=Fri Nov 22 04:46:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040595, encodeId=5555104059502, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Nov 20 16:46:00 CST 2019, time=2019-11-20, status=1, ipAttribution=)]
    2019-11-22 cy0328
  7. [GetPortalCommentsPageByObjectIdResponse(id=1682579, encodeId=1bb916825e963, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Wed Oct 07 14:46:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013100, encodeId=60cf20131001a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 17 18:46:00 CST 2020, time=2020-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871487, encodeId=35a018e14876e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Oct 23 11:46:00 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752373, encodeId=48ba1e523737d, content=<a href='/topic/show?id=82744169af' target=_blank style='color:#2F92EE;'>#caveolin-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4169, encryptionId=82744169af, topicName=caveolin-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7aa036514870, createdName=karmond, createdTime=Mon Jul 27 23:46:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961776, encodeId=05ec1961e76b5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Oct 30 20:46:00 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531485, encodeId=0d961531485da, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri Nov 22 04:46:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629921, encodeId=02c6162992107, content=<a href='/topic/show?id=cb9c5881310' target=_blank style='color:#2F92EE;'>#旁分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58813, encryptionId=cb9c5881310, topicName=旁分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=422221388033, createdName=lfcmxl, createdTime=Fri Nov 22 04:46:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040595, encodeId=5555104059502, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Nov 20 16:46:00 CST 2019, time=2019-11-20, status=1, ipAttribution=)]
    2019-11-22 lfcmxl
  8. [GetPortalCommentsPageByObjectIdResponse(id=1682579, encodeId=1bb916825e963, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Wed Oct 07 14:46:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013100, encodeId=60cf20131001a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 17 18:46:00 CST 2020, time=2020-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871487, encodeId=35a018e14876e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Oct 23 11:46:00 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752373, encodeId=48ba1e523737d, content=<a href='/topic/show?id=82744169af' target=_blank style='color:#2F92EE;'>#caveolin-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4169, encryptionId=82744169af, topicName=caveolin-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7aa036514870, createdName=karmond, createdTime=Mon Jul 27 23:46:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961776, encodeId=05ec1961e76b5, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Oct 30 20:46:00 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531485, encodeId=0d961531485da, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri Nov 22 04:46:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629921, encodeId=02c6162992107, content=<a href='/topic/show?id=cb9c5881310' target=_blank style='color:#2F92EE;'>#旁分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58813, encryptionId=cb9c5881310, topicName=旁分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=422221388033, createdName=lfcmxl, createdTime=Fri Nov 22 04:46:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040595, encodeId=5555104059502, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Nov 20 16:46:00 CST 2019, time=2019-11-20, status=1, ipAttribution=)]
    2019-11-20 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Brit J Cancer:前列腺癌中磷脂酶D2随格林森得分蛋白表达变化研究

磷脂酶D1和D2(PLD1/2)在肿瘤发生过程中具有作用,具体是通过产生脂质磷脂酸信号和下游效应来实现。PDL1的抑制能够阻断前列腺细胞的生长和克隆的形成。最近,有研究人员调查了PLD2在前列腺癌中的作用。研究发现,PLD2蛋白在管腔和基底前列腺上皮细胞中基本等量表达。在来自于不同格林森得分的的PCa组织细胞中,PLD2蛋白表达普遍比非肿瘤组织细胞更高,并且在格林森6-8评分的PCa组织中表达增加

Prostate Cancer P D:阿比特龙和恩杂鲁胺治疗相关的副作用事件分析

当新的治疗方法应用于现实情况中时,来源于临床试验的数据并不是都能够提供充分的信息来判断这些治疗方法的影响情况。最近,有研究人员分析了现实使用中与恩杂鲁胺(ENZ)和阿比特龙(ABI)相关的副作用事件情况。在EudraVigilance (EV)数据库中,研究人员鉴定了13562个ABI治疗个体案例和40599个ENZ治疗个体案例。两种药物产生的副作用事件(AEs)中,超过90%的确定为严重AEs。

Prostate Cancer P D:接受重症监护治疗的转移性前列腺癌患者接受姑息治疗的当前趋势和社会障碍研究

在晚期癌症患者中使用住院病人姑息治疗(IPC)是较为完善的指南建议。之前的分析阐释了泌尿生殖系(GU)癌症患者在4个检查的原发性癌症(肺癌、乳腺癌、结直肠癌和GU)患者中受益于IPC的比例为排序第3。基于这些结果,研究人员在接受重症监护治疗(CCT)的转移前列腺癌(mPCa)患者中调查了IPC使用的当前趋势和预测因子。研究发现,在接受CCT治疗的4168名mPCa患者中,449名(11.3%)进行

EMUC19:Liproca®Depot治疗前列腺癌的IIb期研究达到了主要和次要终点

在第11届欧洲泌尿外科癌症多学科大会(EMUC)上,LIDDS公司公布了Liproca®Depot治疗前列腺癌的IIb期临床试验(LPC-004试验)的最新数据。

Cell Death & Disease:EPHB4抑制能够激活ER应激来促进前列腺癌细胞免疫原性细胞死亡

EPHB4受体在一些上皮肿瘤的发展过程中是具有作用的,并且是非常有前景的治疗靶标。在前列腺肿瘤中,EPHB4过表达并能够促进肿瘤发生。最近,有研究人员指出,EPHB4的高表达与前列腺癌患者的不良预后有关,EPHB4抑制能够在激素敏感性和去势抵抗性前列腺癌细胞中诱导细胞死亡。EPHB4抑制能够减少葡萄糖转运蛋白GLUT3的表达,影响葡萄糖的吸收并减少细胞ATP水平。上述过程与内质网膜应激的激活和肿瘤

院士指导,国产机器人完成首例前列腺癌根治术

近日,在海军军医大学附属长海医院泌尿外科孙颖浩院士亲自指导下,上海市东方医院团队利用机器人辅助腹腔镜下前列腺癌根治术,为一位65岁早期前列腺癌的男性患者成功进行了手术。手术历时约1.5小时。手术采用微创(上海)医疗机器人有限公司自主研发的图迈? Toumai?腔镜手术机器人。这是首例由国产腔镜机器人完成的前列腺癌根治术,由微创(上海)医疗机器人有限公司自主研发,图迈?腔镜机器人也成为中国首个完成高